Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for NEO
| Stock Name | Neo Energy Metals Plc |
| Ticker | NEO(GBP) LSE |
| TYPE | Common Stock |
| Country | UK |
| ISIN | GB00BYWLRL80 |
| LEI | 213800WE14587VRQ5Y10 |
Show aggregate NEO holdings
News associated with NEO
- Stephens Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock
- NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price boosted by equities researchers at Stephens from $6.50 to $11.00 in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has an “overweight” rating on the medical research company’s stock. Stephens’ price target points to a potential upside of 34.31% from the […] - 2025-09-04 04:42:49
- NeoGenomics (NASDAQ:NEO) Price Target Raised to $14.00
- NeoGenomics (NASDAQ:NEO – Free Report) had its price target upped by Needham & Company LLC from $8.00 to $14.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock. Several other brokerages have also recently commented on NEO. Wall Street Zen upgraded shares of […] - 2025-09-01 02:59:14
- Maryland State Retirement & Pension System Decreases Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Maryland State Retirement & Pension System trimmed its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 13.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,401 shares of the medical research company’s stock after selling 5,877 shares […] - 2025-08-17 05:21:02
- Stifel Nicolaus Forecasts Strong Price Appreciation for Neo Performance Materials (TSE:NEO) Stock
- Neo Performance Materials (TSE:NEO – Get Free Report) had its price objective hoisted by investment analysts at Stifel Nicolaus from C$17.50 to C$22.00 in a research report issued on Wednesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 30.41% from the company’s […] - 2025-08-15 02:14:50
- NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of “Hold” by Brokerages
- Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) have earned a consensus rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target […] - 2025-08-12 04:43:02
- NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. IL
- Blair William & Co. IL trimmed its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 25.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,638 shares of the medical research company’s stock after selling 22,312 shares during the quarter. Blair William […] - 2025-08-11 05:52:55
- Harbour Investments Inc. Reduces Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Harbour Investments Inc. reduced its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 50.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 2,835 shares of the medical research company’s stock after selling 2,937 shares during the period. Harbour Investments Inc.’s holdings in NeoGenomics were worth $27,000 as of its most recent SEC filing. […] - 2025-08-11 05:14:54
- NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Federated Hermes Inc.
- Federated Hermes Inc. increased its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 10.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 161,428 shares of the medical research company’s stock after acquiring an additional 15,887 shares during the period. […] - 2025-08-06 05:16:55
- Piper Sandler Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
- NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by Piper Sandler from $12.00 to $11.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Piper Sandler’s target price indicates a potential upside of 95.73% from the stock’s previous close. […] - 2025-08-06 02:18:47
- NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by TD Asset Management Inc
- TD Asset Management Inc cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 57.5% during the first quarter, HoldingsChannel reports. The firm owned 89,910 shares of the medical research company’s stock after selling 121,522 shares during the period. TD Asset Management Inc’s holdings in NeoGenomics were worth $853,000 as of its most recent […] - 2025-08-05 05:32:52
- NeoGenomics (NASDAQ:NEO) Given Market Perform Rating at William Blair
- William Blair reaffirmed their market perform rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report published on Tuesday, MarketBeat.com reports. A number of other equities analysts also recently commented on NEO. Leerink Partners downgraded NeoGenomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock […] - 2025-07-30 04:34:56
- NeoGenomics (NASDAQ:NEO) Hits New 52-Week Low Following Weak Earnings
- NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $5.00 and last traded at $5.41, with a volume of 1442341 shares trading hands. The stock had previously closed at $6.46. The medical research company reported ($0.08) […] - 2025-07-30 02:14:46
- VBK's Underlying Holdings Could Mean 12% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:30
- Nisa Investment Advisors LLC Has $177,000 Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)
- Nisa Investment Advisors LLC lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 56.7% in the first quarter, Holdings Channel.com reports. The institutional investor owned 18,698 shares of the medical research company’s stock after selling 24,517 shares during the quarter. Nisa Investment Advisors LLC’s holdings in NeoGenomics were worth $177,000 as of its […] - 2025-07-18 05:13:01
- NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Illinois Municipal Retirement Fund
- Illinois Municipal Retirement Fund lessened its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 5.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,233 shares of the medical research company’s stock after selling 3,533 shares during the quarter. Illinois […] - 2025-07-04 04:46:51
- Neo Performance Materials (TSE:NEO) Hits New 1-Year High After Dividend Announcement
- Neo Performance Materials Inc. (TSE:NEO – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after the company announced a dividend. The company traded as high as C$12.81 and last traded at C$12.54, with a volume of 171331 shares trading hands. The stock had previously closed at C$12.27. The newly announced […] - 2025-06-20 02:10:48
- ProShare Advisors LLC Increases Position in NeoGenomics, Inc. (NASDAQ:NEO)
- ProShare Advisors LLC increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 44.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,445 shares of the medical research company’s stock after purchasing an additional 11,831 shares during the quarter. […] - 2025-05-26 05:49:09
- Tower Research Capital LLC TRC Cuts Stake in NeoGenomics, Inc. (NASDAQ:NEO)
- Tower Research Capital LLC TRC cut its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 80.8% during the 4th quarter, HoldingsChannel reports. The firm owned 2,449 shares of the medical research company’s stock after selling 10,292 shares during the quarter. Tower Research Capital LLC TRC’s holdings in NeoGenomics were worth $40,000 as of its […] - 2025-05-14 04:24:47
- Neo Performance Materials (TSE:NEO) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says
- Neo Performance Materials (TSE:NEO – Get Free Report) had its target price boosted by equities research analysts at Stifel Nicolaus from C$16.50 to C$17.50 in a research report issued to clients and investors on Monday,BayStreet.CA reports. Stifel Nicolaus’ price target would suggest a potential upside of 58.80% from the stock’s current price. Neo Performance Materials […] - 2025-05-14 02:24:49
- Schonfeld Strategic Advisors LLC Sells 54,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
- Schonfeld Strategic Advisors LLC cut its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 76.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 16,280 shares of the medical research company’s stock after selling 54,330 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in NeoGenomics were worth $268,000 as of its […] - 2025-05-13 05:42:51
- NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com
- NeoGenomics (NASDAQ:NEO – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. Other equities research analysts also recently issued reports about the company. The Goldman Sachs Group cut their price target on NeoGenomics from $15.00 to $10.00 and set a […] - 2025-05-13 04:28:54
- Voya Investment Management LLC Sells 5,003,158 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
- Voya Investment Management LLC trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 98.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,688 shares of the medical research company’s stock after selling 5,003,158 shares during the quarter. Voya […] - 2025-05-07 05:57:02
- Hsbc Holdings PLC Trims Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Hsbc Holdings PLC reduced its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 7.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,569 shares of the medical research company’s stock after selling 2,430 shares during the quarter. Hsbc Holdings PLC’s holdings […] - 2025-05-07 04:56:56
- Needham & Company LLC Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
- NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by research analysts at Needham & Company LLC from $18.00 to $8.50 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Needham & Company LLC’s target price would indicate a potential upside […] - 2025-05-01 02:52:52
- NeoGenomics (NASDAQ:NEO) Shares Gap Down Following Weak Earnings
- NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report)’s share price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $9.97, but opened at $9.64. NeoGenomics shares last traded at $7.59, with a volume of 85,531 shares changing hands. The medical research company reported ($0.08) earnings per […] - 2025-04-30 03:12:52
- Barclays PLC Has $3.95 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Barclays PLC increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 239,438 shares of the medical research company’s stock after buying an additional 8,537 shares during the quarter. Barclays PLC […] - 2025-04-28 05:34:55
- Invesco Ltd. Decreases Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Invesco Ltd. reduced its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 6.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 410,967 shares of the medical research company’s stock after selling 27,789 shares during the quarter. Invesco Ltd. owned approximately 0.32% […] - 2025-04-25 05:08:53
- Surprising Analyst 12-Month Target For RWJ
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-24 08:26:04
- Sterling Capital Management LLC Grows Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
- Sterling Capital Management LLC lifted its position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 788.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,706 shares of the medical research company’s stock after buying an additional 3,289 shares during the period. […] - 2025-04-24 05:46:54
- Rockefeller Capital Management L.P. Acquires 16,831 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
- Rockefeller Capital Management L.P. grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 49.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,082 shares of the medical research company’s stock after acquiring an additional 16,831 shares during the period. Rockefeller Capital […] - 2025-04-23 05:41:01
iShares MSCI World Small Cap UCITS ETF USD (Acc) NEO holdings
| Date | Number of NEO Shares Held | Base Market Value of NEO Shares | Local Market Value of NEO Shares | Change in NEO Shares Held | Change in NEO Base Value | Current Price per NEO Share Held | Previous Price per NEO Share Held |
|---|
| 2025-10-15 (Wednesday) | 106,091 | USD 1,057,727 | USD 1,057,727 | | | | |
| 2025-10-10 (Friday) | 105,428 | USD 959,395 | USD 959,395 | | | | |
| 2025-10-08 (Wednesday) | 105,428 | USD 966,775 | USD 966,775 | | | | |
| 2025-10-07 (Tuesday) | 105,428 | USD 952,015 | USD 952,015 | 442 | USD -3,358 | USD 9.03 | USD 9.1 |
| 2025-10-06 (Monday) | 104,986 | USD 955,373 | USD 955,373 | 0 | USD 0 | USD 9.1 | USD 9.1 |
| 2025-10-03 (Friday) | 104,986 | USD 955,373 | USD 955,373 | 0 | USD 12,599 | USD 9.1 | USD 8.98 |
| 2025-10-02 (Thursday) | 104,986 | USD 942,774 | USD 942,774 | 0 | USD 27,821 | USD 8.98 | USD 8.715 |
| 2025-10-01 (Wednesday) | 104,986 | USD 914,953 | USD 914,953 | 0 | USD 104,461 | USD 8.715 | USD 7.72 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NEO by Blackrock for IE00BF4RFH31
Show aggregate share trades of NEO| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 442 | | | 9.030* | | 10.73 |
| 2025-09-08 | SELL | -884 | | | 7.930* | | 10.85 Profit of 9,592 on sale |
| 2025-08-15 | BUY | 448 | | | 6.210* | | 10.88 |
| 2025-08-07 | BUY | 1,350 | | | 5.760* | | 10.93 |
| 2025-07-29 | BUY | 446 | | | 5.250* | | 11.12 |
| 2025-07-14 | BUY | 892 | | | 7.180* | | 11.30 |
| 2025-06-30 | BUY | 892 | | | 7.310* | | 11.47 |
| 2025-06-25 | BUY | 1,338 | | | 7.180* | | 11.55 |
| 2025-06-20 | SELL | -226 | | | 7.000* | | 11.63 Profit of 2,629 on sale |
| 2025-06-12 | SELL | -1,792 | | | 7.390* | | 11.81 Profit of 21,164 on sale |
| 2025-06-02 | BUY | 678 | | | 7.170* | | 12.05 |
| 2025-05-28 | BUY | 450 | | | 7.420* | | 12.15 |
| 2025-05-14 | BUY | 222 | | | 7.960* | | 12.50 |
| 2025-05-13 | BUY | 444 | | | 8.360* | | 12.53 |
| 2025-05-07 | BUY | 672 | | | 8.000* | | 12.67 |
| 2025-04-28 | BUY | 219 | | | 9.970* | | 12.97 |
| 2025-04-16 | BUY | 2,860 | | | 9.560* | | 13.20 |
| 2025-04-14 | BUY | 440 | | | 9.720* | | 13.26 |
| 2025-04-08 | SELL | -442 | | | 8.200* | | 13.43 Profit of 5,937 on sale |
| 2025-04-04 | SELL | -448 | | | 8.780* | | 13.52 Profit of 6,058 on sale |
| 2025-03-28 | BUY | 2,220 | | | 9.620* | | 13.69 |
| 2025-03-12 | SELL | -446 | | | 10.230* | | 14.23 Profit of 6,346 on sale |
| 2025-03-04 | SELL | -442 | | | 9.340* | | 14.50 Profit of 6,407 on sale |
| 2025-02-26 | SELL | -880 | | | 10.400* | | 14.73 Profit of 12,964 on sale |
| 2025-02-13 | BUY | 220 | | | 13.910* | | 15.02 |
| 2025-02-12 | BUY | 880 | | | 13.780* | | 15.04 |
| 2025-01-27 | BUY | 218 | | | 15.040* | | 15.24 |
| 2025-01-23 | BUY | 218 | | | 14.660* | | 15.25 |
| 2024-12-09 | BUY | 7,848 | | | 17.910* | | 15.17 |
| 2024-12-04 | BUY | 434 | | | 18.010* | | 15.00 |
| 2024-12-03 | BUY | 651 | | | 17.820* | | 14.94 |
| 2024-11-19 | BUY | 1,308 | | | 15.360* | | 14.25 |
| 2024-11-18 | BUY | 436 | | | 15.010* | | 14.23 |
| 2024-11-12 | BUY | 868 | | | 16.330* | | 14.16 |
| 2024-11-11 | BUY | 217 | | | 16.350* | | 14.01 |
| 2024-11-11 | BUY | 217 | | | 16.350* | | 14.01 |
| 2024-11-07 | BUY | 1,080 | | | 15.820* | | 13.73 |
| 2024-11-07 | BUY | 1,080 | | | 15.820* | | 13.73 |
| 2024-10-23 | BUY | 434 | | | 13.070* | | 13.19 |
| 2024-10-23 | BUY | 434 | | | 13.070* | | 13.19 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NEO
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 231,433 | 0 | 663,130 | 34.9% |
| 2025-09-18 | 403,022 | 0 | 949,140 | 42.5% |
| 2025-09-17 | 290,753 | 0 | 2,536,222 | 11.5% |
| 2025-09-16 | 170,858 | 0 | 439,502 | 38.9% |
| 2025-09-15 | 389,168 | 1 | 1,846,003 | 21.1% |
| 2025-09-12 | 259,918 | 886 | 717,778 | 36.2% |
| 2025-09-11 | 435,538 | 145 | 1,116,865 | 39.0% |
| 2025-09-10 | 235,763 | 860 | 527,563 | 44.7% |
| 2025-09-09 | 297,187 | 0 | 493,661 | 60.2% |
| 2025-09-08 | 323,514 | 562 | 551,078 | 58.7% |
| 2025-09-05 | 211,775 | 0 | 461,513 | 45.9% |
| 2025-09-04 | 443,969 | 90 | 943,712 | 47.0% |
| 2025-09-03 | 650,201 | 5,877 | 1,476,976 | 44.0% |
| 2025-09-02 | 1,043,844 | 131 | 2,012,765 | 51.9% |
| 2025-08-29 | 2,044,587 | 25,051 | 4,468,084 | 45.8% |
| 2025-08-28 | 351,246 | 0 | 994,992 | 35.3% |
| 2025-08-27 | 342,001 | 0 | 771,161 | 44.3% |
| 2025-08-26 | 210,127 | 1,145 | 489,984 | 42.9% |
| 2025-08-25 | 224,925 | 0 | 686,973 | 32.7% |
| 2025-08-22 | 196,484 | 1,900 | 631,657 | 31.1% |
| 2025-08-21 | 118,419 | 2,557 | 314,002 | 37.7% |
| 2025-08-20 | 118,137 | 1,262 | 334,258 | 35.3% |
| 2025-08-19 | 88,200 | 500 | 334,432 | 26.4% |
| 2025-08-18 | 108,673 | 0 | 479,896 | 22.6% |
| 2025-08-15 | 229,636 | 0 | 485,011 | 47.3% |
| 2025-08-14 | 149,063 | 0 | 399,190 | 37.3% |
| 2025-08-13 | 150,919 | 4,206 | 473,317 | 31.9% |
| 2025-08-12 | 250,240 | 13,664 | 698,442 | 35.8% |
| 2025-08-11 | 253,103 | 654 | 792,367 | 31.9% |
| 2025-08-08 | 209,748 | 679 | 661,213 | 31.7% |
| 2025-08-07 | 248,523 | 1,162 | 696,340 | 35.7% |
| 2025-08-06 | 200,287 | 111 | 524,544 | 38.2% |
| 2025-08-05 | 259,914 | 0 | 910,814 | 28.5% |
| 2025-08-04 | 315,143 | 18,765 | 1,067,212 | 29.5% |
| 2025-08-01 | 507,215 | 571 | 1,592,222 | 31.9% |
| 2025-07-31 | 675,567 | 0 | 1,627,464 | 41.5% |
| 2025-07-30 | 609,966 | 16,655 | 3,677,284 | 16.6% |
| 2025-07-29 | 1,671,621 | 184,370 | 6,062,518 | 27.6% |
| 2025-07-28 | 409,399 | 649 | 1,227,783 | 33.3% |
| 2025-07-25 | 141,842 | 0 | 512,519 | 27.7% |
| 2025-07-24 | 107,988 | 200 | 594,748 | 18.2% |
| 2025-07-23 | 130,521 | 1 | 864,788 | 15.1% |
| 2025-07-22 | 140,086 | 6,138 | 663,588 | 21.1% |
| 2025-07-21 | 166,086 | 0 | 589,954 | 28.2% |
| 2025-07-18 | 262,161 | 114 | 523,622 | 50.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.